Picotamide is a dually active TXA2R (thromboxane A2) and TXA synthase (thromboxane A2 synthase) inhibitor. It has been shown to exhibit platelet inhibitory effects ex vivo and in vitro. It suppresses arachidonic acid, low-dose collagen, and TXA2-induced human platelet aggregation. However, it does not afftect A23187 induced aggregation or primary aggregation by ADP. It has been shown to inhibit the synthesis of TXA2 by platelets in a dose dependent fashion. It has been reported to enhance PGE2 formation, and enhance PGI2 formation by aspirinated endothelial cells. It has also been shown to raise intraplatelet cAMP levels in platelets stimulated with arachidonic acid.
1. Modesti, P.A., et al. 1989. Eur. J. Pharmacol. 169: 85-93. PMID: 2532145
2. Gresele, P., et al. 1989. Thromb. Haemost. 61: 479-484. PMID: 2552606
3. Berrettini, M., et al. 1990. Eur. J. Clin. Pharmacol. 39: 495-500. PMID: 1963845